Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus) announced that its subsidiary, EXINI Diagnostics AB (EXINI), has entered into a collaboration with the Prostate Cancer Clinical Trials Consortium (PCCTC) to advance artificial intelligence (AI)-enabled imaging biomarkers in prostate cancer.

Study published in Clinical Genitourinary Cancer details the first examining radium-223 in pain palliation using standard doses and contemporary pain end points radium-223, and demonstrated radium-223’s ability to palliate pain in a clinically meaningful manner in nearly one-half of enrolled patients.

The Diversity Working Group of the IRONMAN registry has developed informed strategies for site selection, recruitment, engagement and retention, and trial design and eligibility criteria to ensure broad inclusion and needs awareness of minority participants.

Manuscript published in JCO Oncology Practice details practical considerations and challenges for germline genetic testing in patients with prostate cancer

Despite known racial disparities, men of color remain underrepresented in prostate cancer clinical trials

Dr Charles Ryan is joined by the leadership of the Prostate Cancer Clinical Trials Consortium, a group that has developed innumerable trials and therapies for advanced prostate cancer.

CellCentric has signed an agreement with the PCCTC to help select and manage US sites for the ongoing evaluation of CCS1477.